Fintel reports that Fmr has filed a 13G/A form with the SEC disclosing ownership of 4.46MM shares of GH Research PLC (GHRS). This represents 8.565% of the company.
In their previous filing dated April 11, 2022 they reported 5.20MM shares and 10.00% of the company, a decrease in shares of 14.35% and a decrease in total ownership of 1.44% (calculated as current - previous percent ownership).
Analyst Price Forecast Suggests 281.89% Upside
As of February 9, 2023, the average one-year price target for GH Research is $39.98. The forecasts range from a low of $31.31 to a high of $48.30. The average price target represents an increase of 281.89% from its latest reported closing price of $10.47.
The projected annual revenue for GH Research is $0MM. The projected annual EPS is -$1.01.
What is the Fund Sentiment?
There are 58 funds or institutions reporting positions in GH Research. This is a decrease of 3 owner(s) or 4.92% in the last quarter. Average portfolio weight of all funds dedicated to GHRS is 0.55%, a decrease of 10.56%. Total shares owned by institutions decreased in the last three months by 2.93% to 32,012K shares.
What are large shareholders doing?
Bvf holds 9,275K shares representing 17.83% ownership of the company. No change in the last quarter.
Ra Capital Management holds 4,898K shares representing 9.42% ownership of the company. No change in the last quarter.
VR Adviser holds 3,333K shares representing 6.41% ownership of the company. In it's prior filing, the firm reported owning 3,186K shares, representing an increase of 4.43%. The firm decreased its portfolio allocation in GHRS by 1.44% over the last quarter.
Rtw Investments holds 2,169K shares representing 4.17% ownership of the company. No change in the last quarter.
Orbimed Advisors holds 1,622K shares representing 3.12% ownership of the company. No change in the last quarter.
GH Research Background Information
(This description is provided by the company.)
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
